Arm Holdings’ Stock Falls 9% On Disappointing Outlook
Arm Holdings’ (ARM) stock is down 9% after the British chipmaker issued forward guidance that disappointed Wall Street.The company reported fiscal fourth-quarter earnings per share (EPS) of $0.55 U.S., which beat the consensus estimate of $0.52 U.S. Revenue in the period totaled $1.24 billion U.S., which was slightly ahead of the $1.23 billion U.S. that was forecast on Wall Street. It was the first time in the company’s 35-year history that its quarterly revenue surpassed $1 billion U.S.Despite the decent print, Arm’s stock is falling after management provided a disappointing outlook for the current quarter, saying they expect sales of $1.05 billion U.S. That was below the $1.10 billion U.S. that analysts had penciled in for the company, sending its share price down almost 10%.Arm is different than other chipmakers in that it makes money by licensing its chip designs to semiconductor companies and smartphone makers such as Apple (AAPL).The company’s most advanced chip called “Armv9” generates higher royalty rates than previous microchips and processors.Until now, Arm appeared to be weathering the tariff volatility better than its American peers and rivals. Many analysts had been optimistic that Arm’s core customer base would remain steady despite uncertainty caused by tariffs and trade wars. But now, Arm’s management team says they had to lower their sales guidance as the business outlook for the remainder of the year has been clouded by potential tariff impacts.Prior to today (May 8), Arm’s stock had declined 3% on the year to trade at $124.19 U.S. a share in New York.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


